FTC Report Reveals $7.3 Billion in Drug Price Markups by Pharmacy Benefit Managers
- The Federal Trade Commission reported that the three largest pharmacy benefit managers earned over $7.3 billion from drug price markups between 2017 and 2022.
- The FTC found that PBMs marked up specialty generic drugs by hundreds or thousands of percent, impacting medications for serious illnesses like HIV and cancer.
- PBM-Affiliated pharmacies received higher reimbursements than independent pharmacies, leading to concerns about potential steering of patients to affiliated providers.
- The FTC Chair, Lina Khan, emphasized the need for investigations into practices inflating drug costs and harming independent pharmacies.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left15Leaning Right3Center20Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
52% Center
L 40%
C 52%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
